Dendreon (NASDAQOTH: DNDNQ ) is a constant target for short-sellers, with shares down by a third for 2012 and the two-year graph looking even worse. But with a very important clinical trial on the way for Dendreon's Provenge in sequence with Johnson & Johnson's (NYSE: JNJ ) drug Zytiga in a pre-chemo cancer indication, is the short-selling over? Motley Fool health care analyst David Williamson tells us why the shorts might be wrong on this one and why Dendreon might be due for a turnaround.
Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? David Williamson answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.